Abstract
Background Despite decades of use, the magnitude of efficacy of narrowband‐ultraviolet B phototherapy (NB‐UVB) for atopic dermatitis (AD) outwith industry‐sponsored trials remains unclear. Objective To evaluate the clinical efficacy of NB‐UVB in AD under real‐world conditions. Methods We conducted a historical inception cohort study using automated recording of drug dispensed to provide an objective treatment outcome in a large population catchment of 420,000 over 15 years. We analysed clinical treatment outcomes, recorded multicentre and prospectively over 15 years, as well as drug dispensed in a large AD treatment cohort (n = 844). Results 70% of AD patients received significantly less topical corticosteroids (TCS) during the 12‐month window after finishing NB‐UVB, compared to the 12‐month window before starting (median reduction from 37.5 to 19.7 gram/month). The number of patients dispensed with oral corticosteroid and antihistamines dropped significantly (from 20% to 10% and from 69% to 31%, respectively), while all AD‐unrelated drugs dispensed remained unchanged. Clinically, NB‐UVB treatment achieved a “clear” or “almost clear” status in 48.7% of patients and 20.4% of patients achieved “moderate clearance”. Treatment outcomes scores were validated by a strong correlation with reduction in AD‐specific drug treatment. Conclusion Our data confirm the significant efficacy of NB‐UVB for AD under conditions of routine care.

This publication has 16 references indexed in Scilit: